| Coronary heart disease

Xarelto vs Atorvaliq

Side-by-side clinical, coverage, and cost comparison for coronary heart disease.
Deep comparison between: Xarelto vs Atorvaliq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsAtorvaliq has a higher rate of injection site reactions vs Xarelto based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Atorvaliq but not Xarelto, including UnitedHealthcare
Sign up to reveal the full AI analysis
Xarelto
Atorvaliq
At A Glance
Oral
Once or twice daily
Factor Xa inhibitor
Oral
Daily
HMG-CoA reductase inhibitor
Indications
  • Atrial Fibrillation
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Venous Thrombosis
  • Coronary heart disease
  • Peripheral Arterial Diseases
  • Coronary heart disease
  • Diabetes Mellitus, Non-Insulin-Dependent
  • Heart failure
  • Hyperlipidemia
  • Hypercholesterolemia, Familial
  • Hypertriglyceridemia
Dosing
Atrial Fibrillation 20 mg once daily with evening meal (CrCl >50 mL/min); 15 mg once daily with evening meal (CrCl <=50 mL/min), oral.
Deep Vein Thrombosis, Pulmonary Embolism 15 mg twice daily with food for 21 days, then 20 mg once daily with food for remaining treatment, oral.
Venous Thrombosis 10 mg once daily with or without food: for recurrence prevention after at least 6 months of standard anticoagulant treatment; or 35 days post-hip replacement surgery; or 12 days post-knee replacement surgery; or 31-39 days total for prophylaxis in acutely ill medical patients, oral.
Coronary heart disease, Peripheral Arterial Diseases 2.5 mg twice daily with or without food, in combination with aspirin 75-100 mg once daily, oral.
Coronary heart disease, Diabetes Mellitus Non-Insulin-Dependent, Heart failure, Hyperlipidemia, Hypertriglyceridemia 10 or 20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily; patients requiring LDL-C reduction >45% may start at 40 mg once daily.
Hypercholesterolemia, Familial (HeFH, pediatric >= 10 years) 10 mg once daily orally on an empty stomach; dosage range 10-20 mg once daily.
Hypercholesterolemia, Familial (HoFH, pediatric >= 10 years) 10-20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily.
Contraindications
  • Active pathological bleeding
  • Severe hypersensitivity reaction to rivaroxaban or any excipient (e.g., anaphylactic reactions)
  • Acute liver failure or decompensated cirrhosis
  • Hypersensitivity to atorvastatin or any excipients in ATORVALIQ
Adverse Reactions
Most common Bleeding complications, wound secretion, pruritus, back pain, abdominal pain, muscle spasm, dizziness, fatigue
Serious Intracranial hemorrhage, gastrointestinal bleeding, fatal bleeding, spinal/epidural hematoma
Postmarketing Agranulocytosis, thrombocytopenia, jaundice, cholestasis, hepatitis, hypersensitivity, anaphylactic reaction, anaphylactic shock, angioedema, hemiparesis, anticoagulant-related nephropathy, eosinophilic pneumonia, Stevens-Johnson syndrome, DRESS, atraumatic splenic rupture
Most common (>=2%) Nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Pancreatitis, fatigue, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, rhabdomyolysis, myositis, dizziness, peripheral neuropathy, cognitive impairment, depression, interstitial lung disease, angioneurotic edema, bullous rashes
Pharmacology
Rivaroxaban is a selective oral Factor Xa (FXa) inhibitor that does not require a cofactor for activity; by inhibiting free FXa and prothrombinase activity, it decreases thrombin generation and indirectly inhibits thrombin-induced platelet aggregation.
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a cholesterol precursor; it lowers plasma cholesterol and LDL levels by inhibiting hepatic cholesterol synthesis and increasing hepatic LDL receptor expression.
View Full FDA Information
View full FDA information
View full FDA information
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Xarelto
  • Covered on 5 commercial plans
  • PA (0/12) · Step Therapy (0/12) · Qty limit (12/12)
View full coverage details ›
No coverage data available for Atorvaliq.
UnitedHealthcare
Xarelto
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
View full coverage details ›
No coverage data available for Atorvaliq.
Humana
Xarelto
  • Covered on 0 commercial plans
  • PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
View full coverage details ›
No coverage data available for Atorvaliq.
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/fillfill
Xarelto withMe Savings Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Atorvaliq.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
XareltoView full Xarelto profile
AtorvaliqView full Atorvaliq profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.